Celaid Therapeutics is pleased to announce its participation in RESI JPM 2026 (Redefining Early Stage Investments – JPM Week), to be held on January 12–13, 2026, at the San Francisco Marriott Marquis in San Francisco, USA. The company will present at the Innovator’s Pitch Challenge during the conference.
Yusuke Inoue, Board Director, COO & CFO of Celaid Therapeutics, is scheduled to speak in the following two pitch sessions:
■ Innovator’s Pitch Challenge Session 8 – Advanced Cell & Gene Therapies
Time: Monday, January 12, 2026 | 3:00–4:00 PM (PST)
■ Showcasing Innovations from Japan and South Korea
Time: Tuesday, January 13, 2026 | 12:00–2:00 PM (PST)
RESI JPM is a leading international life science partnering conference that brings together global investors and innovative biotechnology companies. The Innovator’s Pitch Challenge features a curated selection of cutting-edge life science companies, providing opportunities to hear executive-level pitches, receive live investor feedback, and engage in one-to-one partnering meetings.
During these sessions, Celaid Therapeutics will present its technology platform, pipeline, and long-term business strategy, and will engage in discussions regarding investment opportunities and potential research and development (R&D) collaborations.
We welcome inquiries from investors and strategic partners interested in exploring collaboration opportunities with Celaid Therapeutics.